Vectus Biosystems LimitedASX: VBS

FDA Pre-IND feedback for VB0004

· Issued by Vectus Biosystems Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The FDA's written responses provide supportive guidance on the company's chemistry, manufacturing, and clinical plans for the drug. Vectus plans to incorporate this feedback into its Investigational New Drug package as it prepares for a Phase Ib / IIa study.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

A S X A N N O U N C E M E N T 1 6 N o v e m b e r 2 0 2 6 Encouraging FDA Pre-IND feedback for VB0004 in IPF HIGHLIGHTS • The U.S. Food and Drug Administration's (FDA) written responses have been received from the Division of Pulmonology, Allergy and Critical Care (DPACC). • The feedback...

Vectus Biosystems Limited on 6ix

Earlier from Vectus Biosystems

All Vectus Biosystems news releases